{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T01:48:00Z","timestamp":1782524880350,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["SL2022A04J01892"],"award-info":[{"award-number":["SL2022A04J01892"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jiac.2024.11.012","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T13:38:46Z","timestamp":1732023526000},"page":"102562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical characteristics and risk factors of infection in initially treated patients with multiple myeloma during the induction period"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9804-3441","authenticated-orcid":false,"given":"Qianying","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beihui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingli","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifen","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9983","key":"10.1016\/j.jiac.2024.11.012_bib1","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"Rollig","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jiac.2024.11.012_bib2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.jiac.2024.11.012_bib3","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline therapy of multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jiac.2024.11.012_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jiac.2024.11.012_bib5","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3109\/10428194.2015.1088647","article-title":"Infectious complications in patients with newly diagnosed multiple myeloma: a complication from the past?","volume":"57","author":"de la Rubia","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jiac.2024.11.012_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fimmu.2014.00257","article-title":"Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"5","author":"Tete","year":"2014","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jiac.2024.11.012_bib7","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jiac.2024.11.012_bib8","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jiac.2024.11.012_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","article-title":"Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: a systematic review and meta-analysis","volume":"67","author":"Teh","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jiac.2024.11.012_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.13532","article-title":"Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy","volume":"171","author":"Teh","year":"2015","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.jiac.2024.11.012_bib11","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s00520-014-2550-3","article-title":"Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital","volume":"23","author":"Teh","year":"2015","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.jiac.2024.11.012_bib12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1186\/s12879-020-05412-w","article-title":"Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.jiac.2024.11.012_bib13","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4274\/tjh.2013.0173","article-title":"Infections in hospitalised patients with multiple myeloma: main characteristics and risk factors","volume":"32","author":"Valkovic","year":"2015","journal-title":"Turk J Haematol"},{"issue":"12","key":"10.1016\/j.jiac.2024.11.012_bib14","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.21037\/tcr-21-1627","article-title":"Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma","volume":"10","author":"Huang","year":"2021","journal-title":"Transl Cancer Res"},{"issue":"3","key":"10.1016\/j.jiac.2024.11.012_bib15","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"issue":"26","key":"10.1016\/j.jiac.2024.11.012_bib16","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jiac.2024.11.012_bib17","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/cam4.3762","article-title":"Comparison of efficacy, safety, patients' quality of life, and doctors' occupational stress between lenalidomide-based and bortezomib-based induction in patients with newly diagnosed multiple myeloma","volume":"10","author":"Xu","year":"2021","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.jiac.2024.11.012_bib18","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1590\/S1807-59322011001200010","article-title":"Chronic hepatitis virus infection in patients with multiple myeloma: clinical characteristics and outcomes","volume":"66","author":"Teng","year":"2011","journal-title":"Clinics"},{"issue":"1","key":"10.1016\/j.jiac.2024.11.012_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12879-016-2155-1","article-title":"Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma","volume":"17","author":"Huang","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10.1016\/j.jiac.2024.11.012_bib20","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.clml.2021.02.002","article-title":"Epidemiology and risks of infections in patients with multiple myeloma managed with new generation therapies","volume":"21","author":"Lim","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.jiac.2024.11.012_bib21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/ejh.13190","article-title":"Risk factors for infections in newly diagnosed Multiple Myeloma patients: a Danish retrospective nationwide cohort study","volume":"102","author":"Sorrig","year":"2019","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.jiac.2024.11.012_bib22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41375-021-01506-9","article-title":"Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients","volume":"36","author":"Caro","year":"2022","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.jiac.2024.11.012_bib23","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.3816\/CLM.2003.s.005","article-title":"The implications of anemia in multiple myeloma","volume":"4","author":"Mittelman","year":"2003","journal-title":"Clin Lymphoma"},{"issue":"4","key":"10.1016\/j.jiac.2024.11.012_bib24","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.beha.2005.01.013","article-title":"Renal, hematologic and infectious complications in multiple myeloma","volume":"18","author":"Blade","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6","key":"10.1016\/j.jiac.2024.11.012_bib25","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41375-018-0133-x","article-title":"A predictive model for risk of early grade >\/= 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jiac.2024.11.012_bib26","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00277-020-04125-z","article-title":"Risk and impact of invasive fungal infections in patients with multiple myeloma","volume":"99","author":"Tsai","year":"2020","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.jiac.2024.11.012_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ejh.13066","article-title":"Risk factors for blood stream infections in multiple myeloma: a population-based study of 1154 patients in Denmark","volume":"101","author":"Sorrig","year":"2018","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.jiac.2024.11.012_bib28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-0609.2010.01466.x","article-title":"High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents","volume":"85","author":"Terpos","year":"2010","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.jiac.2024.11.012_bib29","first-page":"230","article-title":"Procalcitonin, C-reactive protein and serum lactate dehydrogenase in the diagnosis of bacterial sepsis, SIRS and systemic candidiasis","volume":"23","author":"Miglietta","year":"2015","journal-title":"Infez Med"},{"issue":"6","key":"10.1016\/j.jiac.2024.11.012_bib30","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s12185-017-2313-2","article-title":"Infectious complications in multiple myeloma receiving autologous stem cell transplantation in the past 10 years","volume":"106","author":"Park","year":"2017","journal-title":"Int J Hematol"},{"issue":"2","key":"10.1016\/j.jiac.2024.11.012_bib31","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood.V63.2.468.468","article-title":"Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients","volume":"63","author":"Bataille","year":"1984","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jiac.2024.11.012_bib32","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.7150\/jca.24288","article-title":"Multiple myeloma index for risk of infection","volume":"9","author":"T","year":"2018","journal-title":"J Cancer"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2400309X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2400309X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:48:12Z","timestamp":1738928892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X2400309X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1341321X2400309X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.11.012","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics and risk factors of infection in initially treated patients with multiple myeloma during the induction period","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102562"}}